Consistent with previous findings, we found that EGFR inhibitor gefitinib alone modestly decreased the cell viability in SW1116 and PC-9 colon cancer cell lines carrying wild-type EGFR gene [27], [28]. The gene discussed is EGFR; the disease is malignant colon neoplasm.